BioWorld Asia

Oct. 21, 2009

Cytos Shares Plunge as Vaccine Trial Misses Main Endpoint

Cytos Biotechnology AG lost almost one-third of its value Friday on news that its therapeutic vaccine for nicotine addiction failed to show efficacy in a Phase II study. (BioWorld International) Read More

Viriom Taking Over Development of HIV Treatments in Roche Deal

New Assay Promises Genetic Analysis of Bacterial Pathogens

Biovitrum, Biogen Idec Eye 2011 Filing for Recombinant Factor IX

Oxford BioMedica Seeks OK to Boost ProSavin Dose Level

EU Spending Watchdog Criticizes Framework Project Structures

On Heels of Expanded Merck Deal, Galapagos Raises $27M

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...